Applying exosomes after microneedling has become close to a default upsell in aesthetic practice, and topical peptides have been sold alongside needling for far longer. When Maritza Mejia teaches microneedling planning, what you add is one of the variables she puts on the same footing as depth and passes: know your depth, know your passes, and know "what else are we adding into it."
This piece answers that last question at the level a clinician needs before charging for an add-on: what has actually been published, how good it is, and what the regulatory position is. The short version is that the evidence is thinner and more industry-entangled than the marketing implies, the regulatory position is clearer and less favorable than most injectors realize, and the documented harms from putting uncharacterized products through a freshly needled barrier are real and in the literature.
None of that means the category is worthless. It means you should be able to say out loud, to a patient, exactly what you are selling and on what basis.
The regulatory position is not ambiguous
There are no FDA-approved exosome products. That is the agency's own language, published in its Public Safety Notification on Exosome Products dated 6 December 2019 and still posted on fda.gov. Exosomes intended for therapeutic use are regulated as drugs and biological products under the Public Health Service Act and the Food, Drug, and Cosmetic Act, which means lawful human administration requires an approved biologics license or an investigational new drug application.
That notification was not issued in the abstract. It followed a cluster of serious adverse events in Nebraska, flagged to FDA by the CDC and investigated with Nebraska's Department of Health and Human Services, in which patients treated with an unapproved exosome product developed bloodstream infections. Fewer than five patients were involved, which is small — and entirely beside the point, because the mechanism of harm was a contaminated biologic administered outside any regulatory pathway.
The follow-on question injectors most often ask is whether exosome products fall under the lighter-touch pathway that covers some tissue allografts. They generally do not. In a warning letter to Kimera Labs, Inc. dated 1 September 2023, FDA classified that company's amniotic-fluid-derived exosome products as drugs under section 201(g) and biological products under section 351(i), stating explicitly that they do not qualify as section 361 human cells, tissues and cellular and tissue-based products, because the material is secreted or extracted rather than transplanted as structural tissue. FDA has continued to issue warning letters to exosome marketers since.
The same letter is also the most concrete public evidence available about manufacturing quality in this sector. Among the agency's findings: environmental bioburden limits FDA considered too permissive, samples frozen prior to sterility testing by a method the agency said had "the potential to destroy any microbial content," an unvalidated aseptic process, and more than 37,000 vials distributed between 2020 and 2022 under those conditions.
A clinician reading a vial label cannot verify any of this. That is the practical situation.
What clinical evidence actually exists for exosomes
Less than the volume of marketing suggests, and almost none of it is about microneedling specifically.
The best-designed human study in the space used a laser, not a needling device. Kwon and colleagues ran a twelve-week prospective, double-blind, randomized, split-face study of human adipose tissue stem cell-derived exosomes combined with fractional CO2 laser for acne scars in twenty-five patients (Acta Dermato-Venereologica, 2020;100:adv00310). The exosome side improved on the ECCA acne scar scale by 32.5% against 19.9% for the control gel side, a statistically significant difference, with less erythema and modestly shorter downtime on the treated side.
That is a genuinely credible design — randomized, blinded, split-face, using a validated scar instrument — and it is fair to describe the result as a real but modest incremental benefit. It is also a single-center study of twenty-five patients, over twelve weeks, in which the exosome and control products were manufactured, purified and supplied by the company that makes the tested product.
The paper most often cited as evidence for topical exosomes in general rejuvenation is weaker. Proffer and colleagues reported six-week results for a topical platelet exosome product in fifty-six subjects (Aesthetic Surgery Journal, 2022;42(10):1185–1193). It is single-arm, non-randomized and unblinded, with no control, using a proprietary composite score, and it was financed in part by the product's manufacturer, with several authors disclosed as employees, co-founders or paid consultants of that company. It supports tolerability. It cannot support an efficacy or comparative claim, and it should not be quoted as though it does.
The gap that matters most for this article: no verified randomized or split-face trial tests topical exosomes applied specifically after microneedling. The human evidence that exists uses fractional laser or straight topical application. Whatever you believe about exosomes after laser, the microneedling combination is an extrapolation, not a studied protocol.
There is one further structural problem. The extracellular vesicle field publishes minimum reporting standards precisely because preparations sold as "exosomes" are frequently under-characterized — the MISEV2023 guidelines (Welsh, Goberdhan, O'Driscoll, Théry, Witwer and colleagues, Journal of Extracellular Vesicles, 2024;13(2):e12404) require reporting of source, isolation method and multi-modal characterization including particle count, size distribution and specific protein markers. Commercial aesthetic products are not generally characterized to that standard, and a high particle count on a certificate of analysis is not the same claim as biologically active exosome content.
What about peptides?
Thin in a different way: strong mechanistic rationale, essentially no dedicated human outcome data in the microneedling context.
Copper tripeptide GHK-Cu has decades of laboratory and animal work behind it supporting fibroblast stimulation, collagen and glycosaminoglycan synthesis, and wound healing. That literature is real and uncontroversial as far as it goes. What it does not include is a human randomized trial of an isolated cosmetic peptide — GHK-Cu, palmitoyl pentapeptide-4, acetyl hexapeptide-8 — applied after microneedling and measured against a control.
The closest verified human trial is Merati and colleagues' randomized study of microneedling with a topical growth factor serum against a hyaluronic acid control in twenty patients (Journal of Clinical and Aesthetic Dermatology, 2020;13(11):22–27). It is worth reading in full because its limitations are instructive: randomized but not blinded, small, funded by the manufacturer of the tested serum, and testing a multi-ingredient proprietary cocktail rather than an isolated peptide. Its results were also genuinely mixed — the active arm did better on texture and hydration, while the control arm did better on tone and melanin index. That is not a result marketing decks tend to quote.
The delivery half of the argument is on firmer footing. The microneedle drug-delivery literature does establish that microchannels substantially increase skin permeability and can deliver high-molecular-weight compounds that intact stratum corneum excludes, with that permeability window closing over hours. But permeability is not efficacy. Demonstrating that a large molecule can cross the barrier is a different claim from demonstrating that a particular commercial serum reaches a therapeutic dermal concentration and produces a measurable clinical outcome. That second step is the one the field has not published.
The harm side is better documented than the benefit side
This is the asymmetry that should change practice, and it is the reason the add-on decision is not risk-free even if you consider the benefit unproven.
Microneedling deliberately creates thousands of open channels through the skin barrier. Anything applied during or immediately after that procedure is being delivered into the dermis, not onto the skin — including preservatives, excipients and any microbial contamination the product carries.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
Soltani-Arabshahi, Wong, Duffy and Powell reported three women who developed facial granulomatous reactions two to fourteen days after microneedling performed with a topical vitamin C serum, with patch testing positive to the product in two of the three and one patient developing systemic hypersensitivity including arthralgia, fever and erythema nodosum (JAMA Dermatology, 2014;150(1):68–72). Treatment required prolonged antibiotic courses and some lesions persisted at follow-up. The serum in that series was a widely sold, entirely ordinary cosmetic product — not an exotic biologic.
Infection is documented too. Wu and colleagues reported PCR-confirmed eczema herpeticum developing within twenty-four hours of microneedling combined with platelet-rich plasma in a nineteen-year-old man, resolving with valacyclovir (Clinical, Cosmetic and Investigational Dermatology, 2022;15:653–655).
Put the Kimera Labs sterility findings next to those two case reports and the risk model is straightforward. A product that has not been manufactured to a validated aseptic standard, whose contents cannot be verified from the label, applied directly into open dermal channels, is a hazard with a published precedent.
Maritza's own framing of the post-microneedling period turns on exactly this: the restrictions she gives patients — no sun, no exercise, no swimming, no heat for the first twenty-four hours — exist "because remember, we are doing microchannels, so we don't want any infection." The same reasoning that governs what the patient does at home should govern what you put on the skin in the chair.
What to do with this
Use products intended and manufactured for intra-procedural application. Sterility and an intended use that matches what you are doing are the minimum bar, and a cosmetic serum formulated for intact skin does not clear it.
Know what you are legally administering. No exosome product has FDA approval. That fact belongs in your consent conversation, in plain language, and the decision to offer the category at all is one to take deliberately rather than by drifting into it because a representative visited.
Do not repeat vendor efficacy claims you cannot source. If a claim rests on a single-arm unblinded manufacturer-funded study, say so, or do not make it.
Separate the variables. If you add an exosome or peptide product to an established needling protocol and the results improve, you have changed two things — the add-on and, usually, the patient's expectations. Staged, documented sessions with controlled photography are the only way to know which one did the work.
Be honest about where the ceiling is. What is supportable today: one good split-face trial showing a modest incremental benefit for exosomes after fractional laser; a plausible delivery mechanism; and a preclinical rationale for peptides. What is not supportable: that any of this is proven for microneedling, or that a specific commercial product performs as its packaging says.
For the comparison between the regenerative categories themselves, see our overview of exosomes, PDRN and PRP, and for the broader picture of how collagen stimulation is approached in aesthetic practice, facial collagen stimulation covers the fundamentals.
Clinicians who intend to work in this category need to understand both the products and their regulatory position. Empire Medical Training's Facial Contouring Injectables workshop covers this group of agents hands-on.
Microneedling and aftercare specifics attributed to Maritza Mejia reflect her clinical practice as taught in Empire Medical Training's hands-on curriculum. This article is educational, is not a substitute for training, and is not legal or regulatory advice.
About the author. Maritza Mejia, FNP, is a family nurse practitioner, a faculty member at Empire Medical Training, and the founder of Long Island Beauty Bar, New York.
Frequently Asked Questions
Are exosome products FDA-approved for aesthetic use?
No. FDA's Public Safety Notification on Exosome Products states there are no FDA-approved exosome products. Therapeutic exosomes are regulated as drugs and biological products requiring a license or an investigational new drug application, and FDA has explicitly rejected the section 361 tissue pathway for at least one manufacturer's exosome products.
Is there evidence that exosomes work after microneedling?
Not directly. The strongest human study — a randomized, double-blind, split-face trial in twenty-five patients — used fractional CO2 laser rather than microneedling and found a modest incremental benefit over vehicle for acne scarring. No verified randomized trial tests topical exosomes specifically after microneedling.
Do topical peptides applied after microneedling improve results?
There is no verified human randomized trial of an isolated cosmetic peptide applied after microneedling. The one close trial used a multi-ingredient growth factor serum, was unblinded, industry-funded, and produced mixed results, with the control arm outperforming on tone and melanin index.
Why is applying serum during microneedling risky?
Because the product enters the dermis through open microchannels rather than sitting on intact skin. A published case series documented facial granulomatous reactions and systemic hypersensitivity after microneedling with a topical vitamin C serum, and viral reactivation has been reported after microneedling with an intra-procedural biologic.
How can a clinician verify what is in an exosome product?
Largely, they cannot. Extracellular vesicle reporting standards require characterization of source, isolation method, particle size distribution and specific protein markers, and commercial aesthetic products are not generally characterized to that standard. A particle count alone does not establish biologically active exosome content.
Disclaimer
This article reflects the clinical opinions and experience of Maritza Mejia, FNP, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
